Cholecystokinin metabolism in man and dogs
- PMID: 1180586
- PMCID: PMC1344019
- DOI: 10.1097/00000658-197510000-00015
Cholecystokinin metabolism in man and dogs
Abstract
We have developed a sensitive, specific and reproducible radioimmunoassay for cholecystokinin (CCK) with which basal levels of CCK of between 400-800 pg/ml have been measured in normal man, in patients with diabetes and with duodenal ulcer disease, and in normal dogs. After a meal, circulating levels of CCK rose to 1000-1200 pg/ml in human subjects. Release of CCK was more rapid in diabetic and duodenal ulcer patients than in normal subjects, but elevated postprandial levels persisted much longer in normal subjects. Patients with the Zollinger-Ellison syndrome had elevated values of cholecystokinin which rose after a meal. Lack of correlation between elevated basal levels of gastrin and CCK in patients with the Zollinger-Ellison syndrome suggest that the hypercholecystokininemia may be absolute. The disappearance half-time of exogenous CCK was about 21/2 minutes in normal subjects as well as in diabetic and duodenal ulcer patients. Studies in dogs demonstrated no uptake of basal levels of cholecystokinin by the kidney; on infusion of exogenous CCK-33, the kidney extracted 43% of the total CCK presented and 56% of the integrated CCK. We conclude that: 1) circulating basal and postprandial levels of CCK may be measured in a reproducible fashion; 2) postprandial release of CCK is more rapid in diabetic and duodenal ulcer patients than in normal man; 3) the disappearance half-time of exogenous CCK in man and dogs is about 21/2 minutes; 4) the kidney is a major site for uptake of CCK.
Similar articles
-
Cholecystokinin metabolism in normal man and patients with duodenal ulcer.Ann R Coll Surg Engl. 1982 Nov;64(6):383-90. Ann R Coll Surg Engl. 1982. PMID: 7137828 Free PMC article.
-
Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.J Physiol Pharmacol. 1994 Dec;45(4 Suppl 1):3-66. J Physiol Pharmacol. 1994. PMID: 7787215 Review.
-
Release of radioimmunologic cholecystokinin in human subjects.Am J Surg. 1984 Jan;147(1):124-9. doi: 10.1016/0002-9610(84)90045-x. Am J Surg. 1984. PMID: 6691538
-
Eradication of Helicobacter pylori and gastrin-somatostatin link in duodenal ulcer patients.J Physiol Pharmacol. 1996 Mar;47(1):161-75. J Physiol Pharmacol. 1996. PMID: 8777296 Clinical Trial.
-
The cckOMA syndrome and its relation to the Zollinger-Ellison syndrome: a diagnostic challenge.Scand J Gastroenterol. 2024 May;59(5):533-542. doi: 10.1080/00365521.2024.2308532. Epub 2024 Feb 1. Scand J Gastroenterol. 2024. PMID: 38299632 Review.
Cited by
-
Radioimmunoassay of gastrointestinal hormones.World J Surg. 1979 Aug 31;3(4):423-31. doi: 10.1007/BF01556101. World J Surg. 1979. PMID: 516754 No abstract available.
-
Lack of effect of the specific cholecystokinin receptor antagonist loxiglumide on cholecystokinin clearance from plasma in man.Br J Clin Pharmacol. 1990 Jun;29(6):770-3. doi: 10.1111/j.1365-2125.1990.tb03701.x. Br J Clin Pharmacol. 1990. PMID: 2378793 Free PMC article. Clinical Trial.
-
Cholecystokinin-induced satiety, a key gut servomechanism that is affected by the membrane microenvironment of this receptor.Int J Obes Suppl. 2016 Dec;6(Suppl 1):S22-S27. doi: 10.1038/ijosup.2016.5. Epub 2016 Nov 16. Int J Obes Suppl. 2016. PMID: 28685026 Free PMC article. Review.
-
Alterations of exocrine pancreas in end-stage renal disease. Do they reflect a clinically relevant uremic pancreopathy?Dig Dis Sci. 1995 Dec;40(12):2576-81. doi: 10.1007/BF02220444. Dig Dis Sci. 1995. PMID: 8536515
-
Biliary motility.Gut. 1990 May;31(5):571-82. doi: 10.1136/gut.31.5.571. Gut. 1990. PMID: 2190869 Free PMC article. Review. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources